Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels

European Journal of Endocrinology

Volumn 163, Issue 3, 2010, Pages 469-477

  Cuevas Ramos, Daniel ^a   Almeda Valdes, Paloma ^a   Gómez Pérez, Francisco J ^a   Elena Meza Arana, Clara ^a   Cruz Bautista, Ivette ^a   Arellano Campos, Olimpia ^a   Navarrete López, Mariana ^a   Aguilar Salinas, Carlos A ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL BINDING PROTEIN 4; URIC ACID;

ARTICLE; BLUE COLLAR WORKER; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOTOR ACTIVITY; TIME FACTORS; URIC ACID;

EID: 77956276954     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0454     Document Type: Article

References (36)

1. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR & Shanafelt AB. FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 2005 115 1627-1635.
2. Nishimura T, Nakatake Y, Konishi M & Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochimica et Biophysica Acta 2000 1492 203-206.
3. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SX, Hammer RE, Mangelsdorf DJ & Kliewer SA. Endocrine regulation of the fasting response by PPAR-alfa-mediated induction of FGF21. Cell Metabolism 2007 5 415-425.
4. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS & Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 2007 5 426-437. (Pubitemid 46825495)
5. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A & Rydén M. FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. FEBS Letters 2008 582 1725-1730.
6. Kharitonenkov A, Wroblewski WJ, Koester A, Chen YF, Clutinger CK, Tango XT, Hansen BC, Shanafelt AB & Etgen GJ. The metabolic state of diabetic monkeys is regulated by FGF21. Endocrinology 2007 148 774-781.
7. Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M, Meinus S, Reinecke F, Möhlig M, Weickert MO, Clemenz M, Pfeiffer A, Kintscher U, Spuler S & Spranger J. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009 58 1532-1538.
8. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA & Tripathy D. Circulating fibroblast growth factor-21 (FGF-21) is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009 32 1542-1546.
9. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS & Xu A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008 57 1246-1253.
10. Huating Li, Yuqian Bao, Aimin Xu, Xiaoping Pan, Junxi Lu, Haiya Wu, Huijuan Lu, Kunsan Xiang & Weiping Jia. Serum fibroblast growth factor 21 is associated with adverse lipids profiles and γ-glutamyltransferase but not insulin sensitivity in chinese subjects. Journal of Clinical Endocrinology and Metabolism 2009 94 2151-2156.
11. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H & Boden G. Circulating FGF21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes 2007 116 65-68.
12. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L & Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005 436 356-362. (Pubitemid 41065039)
13. Janke J, Engeli S, Boschmann M, Adams F, Böhnke J, Luft FC, Sharma AM & Jordan J. Retinol-binding protein 4 in human obesity. Diabetes 2006 55 2805-2810.
14. Diez JJ & Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. European Journal of Endocrinology 2003 148 293-300. (Pubitemid 36410714)
15. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R & Kadowaki T. Measurement of the high-molecular weight form adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006 29 1357-1362.
16. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ & Lam KS. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. Journal of Biological Chemistry 2005 280 18073-18080.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001 285 2486-2497.
18. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA & Costa F. Diagnosis and management of the metabolic syndrome: and American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005 112 2735-2752.
19. Matthews DR, Hosker JO, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985 28 412-419.
20. López-Alvarenga JC, Reyes-Díaz S, Castillo-Martínez L, Dávalos-Ibáñez A & González-Barranco J. Reproducibility and sensitivity of a questionnaire on physical activity in a Mexican population. Salud Pública de México 2001 43 306-312.
21. Baecke JA, Burema J, Frijters JE, Hautvast JG & Van der Wiel-Wetzels WA. Obesity in young Dutch adults: II, Daily life style and body mass index. International Journal of Obesity 1983 7 13-24. (Pubitemid 13160601)
22. Paffenbarger RS,Wing AL & Hyde RT. Physical activity as an index of heart attack risk in college alumni. American Journal of Epidemiology 1978 108 161-175.
23. Lundasen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SHE & Rudling M. PPAR-alfa is a key regulator of hepatic FGF21. Biochemical and Biophysical Research Communications 2007 360 437-440.
24. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, Mohammadi M, Finck BN, Mangelsdorf DJ, Kliewer SA & Burgess SC. FGF21 induces PGC-1alfa and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. PNAS 2009 106 10853-10858.
25. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE & Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008 149 6018-6027.
26. Kliewer SA & Mangelsdorf DJ. Fibroblast growth factor 21: from pharmacology to physiology. American Journal of Clinical Nutrition 2010 91 254S-257S.
27. Hojman P, Pedersen M, Nielsen RA, Krogh-Madsen R, Yfanti Ch, Akerstrom Th, Nielsen S & Pedersen BK. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 2009 58 2797-2801.
28. Gälman C, Lundasen T, Kharinonekov A, Eriksson M, Haström I, Dahlin M, Amark P, Angelin B & Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPAR-α activation in man. Cell Metabolism 2008 8 169-174.
29. Boden G. Obesity and free fatty acids. Endocrinology and Metabolism Clinics of North America 2008 37 635-646.
30. Chatzinikolaou A, Fatouros I, Petridou A, Jamurtas A, Avloniti A, Douroudos I, Mastorakos G, Lazaropoulou Ch, Papassotiriou I, Tournis S, Mitrakou A & Mougios V. Adipose tissue lipolysis is upregulated in lean and obese men during acute resistance exercise. Diabetes Care 2008 31 1397-1399.
31. Alsted TJ, Nybo L, Schwelger M, Fledelius C, Jacobsen P, Zimmermann R, Zechner R & Kiens B. Adipose triglyceride lipase in human skeletal muscle is upregulated by exercise training. American Journal of Physiology. Endocrinology and Metabolism 2009 296 E244-E253.
32. Patterson AD, Slanar O, Krausz KW, Höfer CC, Perlík F, Gonzalez FJ & Idle JR. Human urinary metabolomic profile of PPAR-alfa induced fatty acid beta-oxidation. Journal of Proteome Research 2009 8 4293-4300.
33. Kiortsis DN & Elisaf MS. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment. Fundamental & Clinical Pharmacology 2001 15 401-403.
34. Suzuki I, Yamauchi T, Onuma M & Nozaki S. Allopurinol, an inhibitor of uric acid synthesis; can it be used for the treatment of metabolic syndrome and related disorders? Drugs of Today 2009 45 363-378.
35. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J & Mazzali M. Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003 41 1183-1190.
36. Kadowaki T & Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Reviews 2005 26 439-451.